Thermo Fisher Scientific Obinutuzumab Monoclonal Antibody (169F10), Biotin, MonoRab
상품 옵션 정보 | ||||||||
---|---|---|---|---|---|---|---|---|
카탈로그 번호 | CAS 번호 | 설명 | 상태 | 단위 | 판매가 | 할인가 | 가격(VAT포함) | 수량 / 장바구니 / 찜 |
A0196840 | - | Thermo Fisher Scientific A0196840 Obinutuzumab Monoclonal Antibody (169F10), Biotin, MonoRab 40 ug pk | 재고문의 | pk | 0원 | - | 0원 |
다른 상품 둘러보기
Applications
Tested Dilution
Publications
ELISA (ELISA)
0.01-0.1 µg/mL
Product Specifications
Host/Isotype
Rabbit / IgG
Class
Monoclonal
Type
Antibody
Clone
169F10
Immunogen
Obinutuzumab
Conjugate
Biotin Biotin Biotin
Form
Lyophilized
Storage conditions
-20°C or -80°C if preferred
Shipping conditions
Ambient (domestic); Wet ice (international)
Product Specific Information
Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.
Obinutuzumab (Gazyva) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of chronic lymphocytic leukemia and follicular lymphoma. It binds to a unique conformation epitope on CD20 protein, which partially overlaps with the section recognized by rituximab. When Obinutuzumab binds to CD20 on B cells, it makes these cells to be destroyed by the adaptive immune system. GenScript MonoRab™ Anti-Obinutuzumab Antibody (169F10), mAb, Rabbit is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a rabbit immunized with Obinutuzumab.
Target Information
Obinutuzumab is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment. It was approved under the trade name Gazyva by the US FDA in 2013, and as Gazyvaro by the EMA in Europe, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients, and as a second line treatment for follicular lymphoma. Obinutuzumab is a fully humanized monoclonal antibody that binds to an epitope on CD20 that partially overlaps with the epitope recognized by rituximab. Obinutuzumab binds to CD20 on B cells and causes these cells to be destroyed by engaging the adaptive immune system, directly activating intracellular apoptosis pathways, and activating the complement system.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
배송/결제/교환/반품 안내
배송 정보
기본 배송비 |
| 교환/반품 배송비 |
|
---|---|---|---|
착불 배송비 |
| ||
교환/반품 배송비 |
|
결제 및 환불 안내
결제 방법 |
|
---|---|
취소 |
|
반품 |
|
환급 |
|
교환 및 반품 접수
교환 및 반품 접수 기한 |
|
---|---|
교환 및 반품 접수가 가능한 경우 |
|
교환 및 반품 접수가 불가능한 경우 |
|
교환 및 반품 신청
교환 절차 |
|
---|---|
반품 절차 |
|